Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25

Generation Bio Co. (NASDAQ:GBIO) has been assigned an average rating of “Hold” from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $8.8750.

Several research firms have recently commented on GBIO. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Generation Bio in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th. Citigroup reiterated a “market perform” rating on shares of Generation Bio in a report on Wednesday. Wedbush set a $5.50 price objective on shares of Generation Bio and gave the company an “outperform” rating in a report on Tuesday. Finally, Jefferies Financial Group cut shares of Generation Bio from a “buy” rating to a “hold” rating and decreased their target price for the company from $11.00 to $5.00 in a research report on Tuesday.

Institutional Trading of Generation Bio

Institutional investors have recently added to or reduced their stakes in the stock. Shay Capital LLC purchased a new stake in Generation Bio in the third quarter valued at approximately $64,000. ADAR1 Capital Management LLC acquired a new stake in shares of Generation Bio in the third quarter valued at $136,000. AQR Capital Management LLC purchased a new stake in shares of Generation Bio in the 1st quarter valued at $36,000. Cantor Fitzgerald L. P. acquired a new position in Generation Bio during the 3rd quarter worth about $606,000. Finally, Marshall Wace LLP acquired a new position in Generation Bio during the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Price Performance

Shares of Generation Bio stock opened at $5.45 on Tuesday. Generation Bio has a 1-year low of $3.00 and a 1-year high of $12.50. The stock has a market cap of $36.73 million, a P/E ratio of -0.58 and a beta of 1.96. The stock’s 50 day simple moving average is $5.57 and its 200-day simple moving average is $5.15.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.18) by $2.36. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $0.66 million. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%. As a group, research analysts expect that Generation Bio will post -1.75 EPS for the current fiscal year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.